Pityriasis versicolor: an update on pharmacological treatment options
- PMID: 24991691
- DOI: 10.1517/14656566.2014.931373
Pityriasis versicolor: an update on pharmacological treatment options
Abstract
Introduction: Pityriasis versicolor (PV) is a superficial fungal infection caused by Malassezia species; a yeast that naturally colonizes on the skins surface. High efficacy rates are generally obtained with both topical and systemic treatments. However, recurrence rates following successful treatment remain high and there are no dosage guidelines available for administration of systemic antifungal agents that carry risks of adverse events.
Areas covered: This review focused on providing an overview of existing treatments for PV and an introduction to new treatments. A literature search was conducted using the search strategy, pityriasis versicolor OR tinea versicolor. Over the past decade, few new treatments have been introduced, but the efficacy and the dosing regimens of existing treatments have been systematically reviewed. The results of these reviews are discussed.
Expert opinion: Existing topical and systemic agents are both effective treatments against PV. Previous dosage recommendations for systemic agents have been modified based on recent evidence elucidated in systematic reviews. However, the absence of standardized collection and reporting practices in clinical trials precludes any conclusions to be drawn regarding the efficacy and safety of topical and systemic agents in comparison or in concert with each other.
Keywords: pityriasis versicolor; systemic antifungal; tinea versicolor; topical antifungal; treatment.
Similar articles
-
Pityriasis versicolor: a review of pharmacological treatment options.Expert Opin Pharmacother. 2005 Feb;6(2):165-78. doi: 10.1517/14656566.6.2.165. Expert Opin Pharmacother. 2005. PMID: 15757415 Review.
-
In vitro antifungal susceptibility of Malassezia isolates from pityriasis versicolor lesions.Indian J Dermatol Venereol Leprol. 2017 Mar-Apr;83(2):249-251. doi: 10.4103/0378-6323.193617. Indian J Dermatol Venereol Leprol. 2017. PMID: 27852993 No abstract available.
-
Tinea versicolor in dark-skinned individuals.Int J Dermatol. 2014 Feb;53(2):137-41. doi: 10.1111/ijd.12345. Epub 2013 Dec 10. Int J Dermatol. 2014. PMID: 24320140 Review.
-
Pityriasis versicolor.J Eur Acad Dermatol Venereol. 2002 Jan;16(1):19-33. doi: 10.1046/j.1468-3083.2002.00378.x. J Eur Acad Dermatol Venereol. 2002. PMID: 11952286 Review.
-
Can pityriasis versicolor be treated with 2% ketoconazole foam?J Drugs Dermatol. 2014 Jul;13(7):855-9. J Drugs Dermatol. 2014. PMID: 25007370 Clinical Trial.
Cited by
-
Case Report: Scalp pityriasis versicolor may be a neglected problem.Front Pediatr. 2024 Jun 19;12:1361225. doi: 10.3389/fped.2024.1361225. eCollection 2024. Front Pediatr. 2024. PMID: 38962574 Free PMC article.
-
Antimicrobial Photodynamic Therapy for Superficial, Skin, and Mucosal Fungal Infections: An Update.Microorganisms. 2025 Jun 17;13(6):1406. doi: 10.3390/microorganisms13061406. Microorganisms. 2025. PMID: 40572295 Free PMC article. Review.
-
Pityriasis Versicolor-A Narrative Review on the Diagnosis and Management.Life (Basel). 2023 Oct 22;13(10):2097. doi: 10.3390/life13102097. Life (Basel). 2023. PMID: 37895478 Free PMC article. Review.
-
Tinea versicolor: an updated review.Drugs Context. 2022 Nov 14;11:2022-9-2. doi: 10.7573/dic.2022-9-2. eCollection 2022. Drugs Context. 2022. PMID: 36452877 Free PMC article. Review.
-
Bisphosphonates synergistically enhance the antifungal activity of azoles in dermatophytes and other pathogenic molds.mSphere. 2024 Jun 25;9(6):e0024824. doi: 10.1128/msphere.00248-24. Epub 2024 Jun 5. mSphere. 2024. PMID: 38837382 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous